​

GSK (GSK) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GSK Stock Forecast

GSK (GSK) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $58.00, with a high of $85.00 and a low of $36.00. This represents a 65.43% increase from the last price of $35.06.

$30 $41 $52 $63 $74 $85 High: $85 Avg: $58 Low: $36 Last Closed Price: $35.06

GSK Stock Rating

GSK stock's rating consensus is Hold, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (27.27%), 8 Hold (72.73%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 11 8 3 0 Strong Sell Sell Hold Buy Strong Buy

GSK Forecast vs Benchmarks

TypeNameUpside
StockGSK65.43%
SectorHealthcare Stocks 25.20%
IndustryDrug Manufacturers - General Stocks22.62%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$58.00
Last Closing Price$35.06$35.06$35.06
Upside/Downside--65.43%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25123-17
Dec, 24123-17
Nov, 24133-18
Oct, 242341111
Sep, 242241110
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 02, 2024Peter WelfordJefferies$53.00$38.3838.09%51.17%
Apr 11, 2024Vamil DivanGuggenheim$36.00$40.69-11.53%2.68%
Apr 11, 2024Mark PurcellMorgan Stanley$85.00$40.69108.90%142.44%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Nov 15, 2024Deutsche BankHolddowngrade
Oct 31, 2024GuggenheimBuyNeutraldowngrade
Oct 07, 2024JefferiesBuyBuyhold
Oct 01, 2024BarclaysEqual-WeightEqual-Weighthold
Aug 12, 2024JefferiesBuyBuyhold
Jul 22, 2024Morgan StanleyEqual-WeightEqual-Weighthold
Jul 11, 2024GuggenheimBuyBuyhold
Jul 08, 2024UBSNeutraldowngrade
Jul 02, 2024JefferiesBuyBuyhold
Jun 04, 2024JefferiesBuyBuyhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.89$2.19$2.41$1.20-----
Avg Forecast$2.33$2.23$2.68$3.04$3.07$3.25$3.65$3.98$4.06
High Forecast$2.28$2.18$2.59$2.91$2.93$3.12$1.99$3.73$3.91
Low Forecast$2.39$2.28$2.76$3.11$3.23$3.37$4.12$4.19$4.21
Surprise %24.03%-1.79%-10.07%-60.53%-----

Revenue Forecast

$25B $30B $35B $40B $45B $50B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$34.10B$34.11B$29.32B$30.33B-----
Avg Forecast$46.37B$46.08B$35.57B$37.78B$38.70B$40.25B$42.50B$44.48B$45.07B
High Forecast$45.59B$45.31B$34.63B$37.42B$37.19B$38.96B$41.25B$43.17B$43.75B
Low Forecast$47.21B$46.92B$36.42B$38.12B$39.69B$40.92B$43.74B$45.77B$46.39B
Surprise %-26.46%-25.98%-17.55%-19.72%-----

Net Income Forecast

$0 $4B $8B $12B $16B $20B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$5.75B$4.38B$4.92B$4.93B-----
Avg Forecast$9.59B$9.15B$11.01B$12.36B$12.66B$13.33B$12.56B$16.26B$16.69B
High Forecast$9.38B$8.95B$10.63B$11.95B$12.05B$12.82B$8.20B$15.32B$16.06B
Low Forecast$9.82B$9.37B$11.35B$12.78B$13.28B$13.84B$16.93B$17.21B$17.32B
Surprise %-40.06%-52.08%-55.31%-60.14%-----

GSK Forecast FAQ

Is GSK stock a buy?

GSK stock has a consensus rating of Hold, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 8 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that GSK is a neutral investment for most analysts.

What is GSK's price target?

GSK's price target, set by 11 Wall Street analysts, averages $58 over the next 12 months. The price target range spans from $36 at the low end to $85 at the high end, suggesting a potential 65.43% change from the previous close price of $35.06.

How does GSK stock forecast compare to the average forecast of its sector, industry, and investment themes?

GSK stock forecast shows a 65.43% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the drug manufacturers - general stocks industry (22.62%).

What is the breakdown of analyst ratings for GSK over the past three months?

  • January 2025: 14.29% Strong Buy, 28.57% Buy, 42.86% Hold, 0% Sell, 14.29% Strong Sell.
  • December 2024: 14.29% Strong Buy, 28.57% Buy, 42.86% Hold, 0% Sell, 14.29% Strong Sell.
  • November 2024: 12.50% Strong Buy, 37.50% Buy, 37.50% Hold, 0% Sell, 12.50% Strong Sell.

What is GSK’s EPS forecast?

GSK's average annual EPS forecast for its fiscal year ending in December is 3.07 for 2024, a 155.83% increase from the reported $1.2 in 2023. The prediction for 2025 is $3.25, $3.65 for 2026, $3.98 for 2027, and $4.06 for 2028.

What is GSK’s revenue forecast?

GSK's average annual revenue forecast for its fiscal year ending in December is $38.7B for 2024, a 27.59% increase from the reported $30.33B in 2023. The forecast for 2025 is $40.25B, $42.5B for 2026, $44.48B for 2027, and $45.07B for 2028.

What is GSK’s net income forecast?

For its fiscal year ending in December, GSK's average annual net income forecast is $12.66B for 2024, reflecting an 156.98% increase from the reported $4.93B in 2023. The projection for 2025 is $13.33B, $12.56B for 2026, $16.26B for 2027, and $16.69B for 2028.